患有无细胞淋巴瘤激酶重排的肺癌患者在确诊时失去了与劳动力市场的联系

Pub Date : 2024-03-13 DOI:10.2217/lmt-2023-0013

Jon Lykkegaard Andersen, Jakob Sidenius Johansen, E. Urbanska, P. Meldgaard, Peter Hjorth-Hansen, Charlotte Kristiansen, Miroslaw Stelmach, Eric Santoni-Rugiu, M. P. Ulhoi, Betina Højgaard, Morten Sall Jensen, A. B. Dydensborg, C. Dünweber, K. H. Hansen

{"title":"患有无细胞淋巴瘤激酶重排的肺癌患者在确诊时失去了与劳动力市场的联系","authors":"Jon Lykkegaard Andersen, Jakob Sidenius Johansen, E. Urbanska, P. Meldgaard, Peter Hjorth-Hansen, Charlotte Kristiansen, Miroslaw Stelmach, Eric Santoni-Rugiu, M. P. Ulhoi, Betina Højgaard, Morten Sall Jensen, A. B. Dydensborg, C. Dünweber, K. H. Hansen","doi":"10.2217/lmt-2023-0013","DOIUrl":null,"url":null,"abstract":"Aim: The main purpose of the present study was to investigate the labor market affiliation of ALK+ NSCLC patients in long-term treatment as well as overall survival and incidence/prevalence. Materials & methods: Nationwide retrospective study of all patients with ALK+ NSCLC in Denmark diagnosed between 2012 and 2018. Results: During the study period ALK+ NSCLC patients had a median overall survival of 44.0 months and a 7.8-fold increase in disease prevalence. Six months prior to diagnosis, 81% of ALK+ NSCLC patients ≤60 years of age were employed. At the end of the 18-month follow-up period, 36% were employed. Conclusion: ALK+ NSCLC patients have prolonged survival following diagnosis, but a large fraction of patients lose affiliation with the labor market.","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Lung cancer patients with anaplastic lymphoma kinase rearrangement lose affiliation with labor market at diagnosis\",\"authors\":\"Jon Lykkegaard Andersen, Jakob Sidenius Johansen, E. Urbanska, P. Meldgaard, Peter Hjorth-Hansen, Charlotte Kristiansen, Miroslaw Stelmach, Eric Santoni-Rugiu, M. P. Ulhoi, Betina Højgaard, Morten Sall Jensen, A. B. Dydensborg, C. Dünweber, K. H. Hansen\",\"doi\":\"10.2217/lmt-2023-0013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim: The main purpose of the present study was to investigate the labor market affiliation of ALK+ NSCLC patients in long-term treatment as well as overall survival and incidence/prevalence. Materials & methods: Nationwide retrospective study of all patients with ALK+ NSCLC in Denmark diagnosed between 2012 and 2018. Results: During the study period ALK+ NSCLC patients had a median overall survival of 44.0 months and a 7.8-fold increase in disease prevalence. Six months prior to diagnosis, 81% of ALK+ NSCLC patients ≤60 years of age were employed. At the end of the 18-month follow-up period, 36% were employed. Conclusion: ALK+ NSCLC patients have prolonged survival following diagnosis, but a large fraction of patients lose affiliation with the labor market.\",\"PeriodicalId\":0,\"journal\":{\"name\":\"\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0,\"publicationDate\":\"2024-03-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/lmt-2023-0013\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/lmt-2023-0013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

目的：本研究的主要目的是调查ALK+ NSCLC患者在长期治疗中的劳动力市场归属以及总生存率和发病率/流行率。材料与方法：对丹麦 2012 年至 2018 年间确诊的所有 ALK+ NSCLC 患者进行全国范围的回顾性研究。结果：在研究期间，ALK+ NSCLC 患者的中位总生存期为 44.0 个月，疾病患病率增加了 7.8 倍。确诊前6个月，81%年龄在60岁以下的ALK+ NSCLC患者有工作。在18个月的随访期结束时，36%的患者有工作。结论ALK+NSCLC患者在确诊后生存期延长，但很大一部分患者失去了与劳动力市场的联系。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

Lung cancer patients with anaplastic lymphoma kinase rearrangement lose affiliation with labor market at diagnosis

Aim: The main purpose of the present study was to investigate the labor market affiliation of ALK+ NSCLC patients in long-term treatment as well as overall survival and incidence/prevalence. Materials & methods: Nationwide retrospective study of all patients with ALK+ NSCLC in Denmark diagnosed between 2012 and 2018. Results: During the study period ALK+ NSCLC patients had a median overall survival of 44.0 months and a 7.8-fold increase in disease prevalence. Six months prior to diagnosis, 81% of ALK+ NSCLC patients ≤60 years of age were employed. At the end of the 18-month follow-up period, 36% were employed. Conclusion: ALK+ NSCLC patients have prolonged survival following diagnosis, but a large fraction of patients lose affiliation with the labor market.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助